Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3842387 | 0.83 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL127741 | 0.78 | — | — | |
| SCHEMBL3837885 | 0.74 | — | — | |
| SCHEMBL4508242 | 0.70 | — | — | |
| SCHEMBL3842949 | 0.70 | — | — | |
| SCHEMBL10866796 | 0.70 | — | — | |
| SCHEMBL3120728 | 0.69 | MEN1 (0.34) | — | |
| SCHEMBL2465659 | 0.69 | MEN1 (0.31) | — | |
| SCHEMBL128031 | 0.69 | — | — | |
| SCHEMBL17048724 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1550664-B1 | SILICON COMPOUND | JNC CORP (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-1650214-B1 | Silicon compound | CHISSO CORP (JP) | 2009-11-04 | — | — | EP | disclosed |
| EP-1686133-B1 | Organosilicon compound | CHISSO CORP (JP) | 2008-08-20 | — | — | EP | disclosed |
| US-7399819-B2 | Silicon compound | CHISSO CORPORATION (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7375170-B2 | Organosilicon compound | CHISSO CORPORATION (JP) | 2008-05-20 | — | — | US | disclosed |
| EP-1849788-A1 | Organosilicon compound | Chisso Corporation (JP) | 2007-10-31 | — | — | EP | disclosed |
| EP-1849787-A1 | Organosilicon compound | Chisso Corporation (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-7256243-B2 | Silicon compound | CHISSO CORPORATION (JP) | 2007-08-14 | — | — | US | disclosed |
| US-7235619-B2 | Silsesquioxane derivative | CHISSO CORPORATION (JP) | 2007-06-26 | — | — | US | disclosed |
| US-20060175684-A1 | Organosilicon compound | JNC PETROCHEMICAL CORPORATION (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1686133-A2 | Organosilicon compound | CHISSO CORPORATION (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-7053167-B2 | Silsesquioxane derivative having functional group | CHISSO CORPORATION (JP) | 2006-05-30 | — | — | US | disclosed |
| US-20060094849-A1 | Silicon compound | JNC CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060089504-A1 | Silsesquioxane derivative having functional group | ITO KENYA | 2006-04-27 | — | — | US | disclosed |
| EP-1650214-A2 | Silicon compound | CHISSO CORPORATION (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20050250925-A1 | Silicon compound | JNC CORPORATION (JP) | 2005-11-10 | — | — | US | disclosed |
| US-20050215807-A1 | Silsesquioxane derivative | JNC CORPORATION (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1550664-A1 | SILICON COMPOUND | CHISSO CORPORATION (JP) | 2005-07-06 | — | — | EP | disclosed |
| US-20040068074-A1 | Production process for silsesquioxane derivative having functional group and silsesquioxane derivative | JNC CORPORATION (JP) | 2004-04-08 | — | — | US | disclosed |
| US-20040030084-A1 | Production process for silsesquioxane derivative and silsesquioxane derivative | JNC CORPORATION (JP) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215807-A1 | Silsesquioxane derivative | STS, SFXN1, SULT1A1 | MAPK1 1845/4885 |
| US-20060089504-A1 | Silsesquioxane derivative having functional group | SFXN1, STS, SRM | MAPK1 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.